These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23926179)

  • 1. Vitamin D increases plasma renin activity independently of plasma Ca2+ via hypovolemia and β-adrenergic activity.
    Atchison DK; Harding P; Beierwaltes WH
    Am J Physiol Renal Physiol; 2013 Oct; 305(8):F1109-17. PubMed ID: 23926179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice.
    Fryer RM; Rakestraw PA; Nakane M; Dixon D; Banfor PN; Koch KA; Wu-Wong JR; Reinhart GA
    Nephron Physiol; 2007; 106(4):p76-81. PubMed ID: 17622742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol.
    Repo JM; Rantala IS; Honkanen TT; Mustonen JT; Kööbi P; Tahvanainen AM; Niemelä OJ; Tikkanen I; Rysä JM; Ruskoaho HJ; Pörsti IH
    Kidney Int; 2007 Oct; 72(8):977-84. PubMed ID: 17667981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D receptor agonist VS-105 directly modulates parathyroid hormone expression in human parathyroid cells and in 5/6 nephrectomized rats.
    Sawada K; Wu-Wong JR; Chen YW; Wessale JL; Kanai G; Kakuta T; Fukagawa M
    J Steroid Biochem Mol Biol; 2017 Mar; 167():48-54. PubMed ID: 27989797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of novel vitamin D receptor analog VS-105 and paricalcitol on chronic kidney disease-mineral bone disorder in an experimental model of chronic kidney disease.
    Fujii H; Yonekura Y; Nakai K; Kono K; Goto S; Nishi S
    J Steroid Biochem Mol Biol; 2017 Mar; 167():55-60. PubMed ID: 27818277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.
    Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J
    Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of vitamin D analogs on vascular calcification.
    Cardús A; Panizo S; Parisi E; Fernandez E; Valdivielso JM
    J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
    Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
    Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypercalcemia reduces plasma renin via parathyroid hormone, renal interstitial calcium, and the calcium-sensing receptor.
    Atchison DK; Harding P; Beierwaltes WH
    Hypertension; 2011 Oct; 58(4):604-10. PubMed ID: 21825222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro.
    Balint E; Marshall CF; Sprague SM
    Am J Kidney Dis; 2000 Oct; 36(4):789-96. PubMed ID: 11007682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac effect of vitamin D receptor modulators in uremic rats.
    Mizobuchi M; Ogata H; Yamazaki-Nakazawa A; Hosaka N; Kondo F; Koiwa F; Kinugasa E; Shibata T
    J Steroid Biochem Mol Biol; 2016 Oct; 163():20-7. PubMed ID: 27072785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.
    Riccio E; Sabbatini M; Bruzzese D; Capuano I; Migliaccio S; Andreucci M; Pisani A
    PLoS One; 2015; 10(3):e0118174. PubMed ID: 25781618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D receptor activators upregulate and rescue podocalyxin expression in high glucose-treated human podocytes.
    Verouti SN; Tsilibary EC; Fragopoulou E; Iatrou C; Demopoulos CA; Charonis AS; Charonis SA; Drossopoulou GI
    Nephron Exp Nephrol; 2012; 122(1-2):36-50. PubMed ID: 23548800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol.
    Freundlich M; Quiroz Y; Zhang Z; Zhang Y; Bravo Y; Weisinger JR; Li YC; Rodriguez-Iturbe B
    Kidney Int; 2008 Dec; 74(11):1394-402. PubMed ID: 18813285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.
    Sprague SM; Llach F; Amdahl M; Taccetta C; Batlle D
    Kidney Int; 2003 Apr; 63(4):1483-90. PubMed ID: 12631365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin.
    Chung S; Kim S; Kim M; Koh ES; Shin SJ; Park CW; Chang YS; Kim HS
    PLoS One; 2017; 12(7):e0181757. PubMed ID: 28753620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium balance during calcitriol and paricalcitol administration in healthy humans.
    Hafner V; Rutsch C; Ding R; Heinrich T; Diedrichs L; Schmidt-Gayk H; Walter-Sack I; Bommer J; Mikus G
    Int J Clin Pharmacol Ther; 2008 Mar; 46(3):131-5. PubMed ID: 18397683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the relative effects of 1,24-dihydroxyvitamin D(2) [1, 24-(OH)(2)D(2)], 1,24-dihydroxyvitamin D(3) [1,24-(OH)(2)D(3)], and 1,25-dihydroxyvitamin D(3) [1,25-(OH)(2)D(3)] on selected vitamin D-regulated events in the rat.
    Horst R; Prapong S; Reinhardt T; Koszewski N; Knutson J; Bishop C
    Biochem Pharmacol; 2000 Sep; 60(5):701-8. PubMed ID: 10927029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.
    Mizobuchi M; Finch JL; Martin DR; Slatopolsky E
    Kidney Int; 2007 Sep; 72(6):709-15. PubMed ID: 17597697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of calcitriol and paricalcitol on renal fibrosis in CKD.
    Martínez-Arias L; Panizo S; Alonso-Montes C; Martín-Vírgala J; Martín-Carro B; Fernández-Villabrille S; García Gil-Albert C; Palomo-Antequera C; Fernández-Martín JL; Ruiz-Torres MP; Dusso AS; Carrillo-López N; Cannata-Andía JB; Naves-Díaz M
    Nephrol Dial Transplant; 2021 Apr; 36(5):793-803. PubMed ID: 33416889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.